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IMPROVED FATIGUE AND PHYSICAL FUNCTION ARE CORRELATED WITH
HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS SUBJECTS
TREATED WITH APREMILAST: RESULTS FROM A PHASE 2, RANDOMIZED,
CONTROLLED STUDY
Strand V1, Hu A2, Zhang F2
1Stanford University, Portola Valley, CA, USA, 2Celgene Corporation, Warren, NJ, USA
OBJECTIVES: Psoriatic arthritis (PsA) is an inflammatory arthritis with deleterious
effects on health-related quality of life (HRQOL). We evaluated the effect of apremi-
last (APR) on patient-reported outcomes (PROs) in PsA subjects and the correlation
between the 36-Item Short-Form Health Survey (SF-36) domains and disease-spe-
cific measures of physical function and fatigue.METHODS:A phase II, multicentre,
double-blind, placebo-controlled study randomised 204 subjects with active PsA
(duration 6 months; 3 swollen joints; 3 tender joints) 1:1:1 to oral APR 20mg
BID (APR20), 40mg QD (APR40), or placebo for 12 weeks. PROs included Functional
Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), Health Assessment
Questionnaire–Disability Index (HAQ-DI), pain visual analogue scale (VAS), and
SF-36 domain scores. Correlations between the HAQ-DI, pain VAS, and FACIT-F and
the SF-36 Physical Function (PF), Bodily Pain (BP) and Vitality (VT) domains were
described with statistical significance. RESULTS: At week 12, mean change in PF,
BP, and VT was 2.1, 2.7, and 3.1 with placebo; 6.2 (P0.012 versus placebo), 11.5
(P0.001 versus placebo), and 6.6 (P0.05 versus placebo) with APR20; and 3.8, 7.9
(P0.037 versus placebo), and 3.7 with APR40, respectively. Mean change in HAQ-DI
was0.1,0.2, and0.2 with placebo, APR20, and APR40. Mean change in FACIT-F
was 0.5, 4.1 (P0.025), and 4.3 with placebo, APR20, and APR40. Mean percent
change in pain VAS was 7.4%,14.5%, and15.1% with placebo, APR20, and APR40.
Moderate (0.300.60) and statistically significant (P0.001) correlations were ev-
ident between pain VAS and BP (0.55), HAQ-DI and PF (0.43), and FACIT-F and VT
(0.55). High (0.60), statistically significant (P0.001) correlations were observed for
FACIT-F versus VT (0.66) with APR20 and HAQ-DI versus PF (0.73) with APR40.
CONCLUSIONS: Treatment of PsA with APR20 was associated with statistically
significant improvements versus placebo in FACIT-F and HRQOL. Moderate to high
correlations were evident among PROs.
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NEW DEVELOPMENTS IN THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE
(ASQOL) SCALE
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OBJECTIVES: The PsAQoL is a measure of quality of life (QoL) specific to psoriatic
arthritis (PsA) first published in 2003. Content of the measure was derived entirely
from qualitative interviews conducted with UK PsA patients. New language ver-
sions have since been developed for several European countries, the US, Canada,
Argentina and Brazil. Interest in the PsAQoL has increased lately due to the need to
determine changes in QoL associated with new biological treatments. In recent
years there has been a move towards conducting clinical trials in developing coun-
tries. This has increased interest in adapting patient-reported outcome measures
developed in Europe and the United States for use in new regions of the World. An
important question remains to be answered; can such measures provide valid
assessment of QoL in these regions? METHODS: New adaptations are currently
being produced for Eastern Europe (4), the Middle East (2), Central and South Amer-
ica (2) and Asia (5). The measures are being translated (using the two panel meth-
odology required for needs-based measures) and tested with local patients by
means of cognitive debriefing interviews. RESULTS: To date cognitive debriefing
interviews have confirmed the adapted measures’ acceptability to patients who
found it easy to understand and complete. The adaptations also have good internal
consistency (alphas 0.85) and reproducibility (test-retest reliability coefficients:
0.85). The adaptations also exhibited construct validity by their ability to distin-
guish groups of PsA patients that varied by perceived disease severity and general
health and by correlating as expected (moderately) with the Nottingham Health
Profile. CONCLUSIONS: It is intended to use Item Response Theory analyses to
determine whether respondents in the developing countries answer the PsAQoL in
the same way as those in Western countries. This will show whether the scales
work validly in the developing countries.
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SENSITIVITY OF PRO’S TO DETECT CHANGES IN QUALITY OF LIFE IN PATIENTS
TREATED WITH A BIOLOGIC AGENT
Pumford N1, Wade A1, Crawford G1, Mcconnachie A2
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OBJECTIVES: To investigate whether patient reported outcomes in patients who
had been prescribed etanercept, an anti –TNF inhibitor, by their specialist could
detect changes in quality of life over time. A longitudinal evaluation was designed
to collect naturalistic data about their condition, medications and health care
experience. METHODS: The evaluation was conducted throughout the UK using a
web-based system supplemented by telephone reporting PROBE (patient reported
outcomes based evaluation). Outcome measures included demographic data, the
condition, previous treatment, current medications, patients’ experiences of their
condition, treatment and healthcare and quality of life. RESULTS: A total of 344
people participated in the evaluation at baseline, 290 online and 54 by telephone
with a mean age of 53 years and 62% female. 191 of these patients had Rheumatoid
Arthritis, 44 Psoriatic Arthritis, 43 Ankylosing Spondylitis, 35 psoriasis and 31 oth-
er/missing data. Patients were severely affected by their condition as noted on their
quality of life measures at baseline. Treatment had a marked beneficial effect for
patients as recorded by all measurement tools. All scores given in order. Baseline
month 6 mean (SD) clinical global impression 1 worst health 7 best health 3.15 (1.09)
to 4.31 (1.50) p0.001. EQ 5D Questionnaire 0.0 worst health 1.0 best health 0.39
(0.34) to 0.64 (0.27) p0.001. DLQI 30 worst effect 0 no effect on life 14.57 (6.74) to 3.69
(6.14) p0.001. HAQ. 0 no difficulty 3 unable to perform action 1.77 (0.63) to 1.25
(0.73) p0.001. CONCLUSIONS: This evaluation shows that patients have signifi-
cant impairment of their quality of life before commencing a biologic agent across
a range of conditions. Treatment with the biologic agent showed a sustained im-
provement in their quality of life up to 6 months. The PROBE methodology (web-
based system supplemented by telephone reporting) successfully captured
changes in patient reported quality of life measures.
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QUALITY OF LIFE FOR THAI HIP FRACTURE PATIENTS: ASSESSMENTS WITH
MEDICAL OUTCOMES STUDY, A 36-ITEM SHORT FORM SURVEY (MOS SF-36)
AND ONE-YEAR HEALTH CARE RESOURCE UTILIZATION IN A PUBLIC HOSPITAL
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OBJECTIVES:Hip fracture is a major health burden in Thailand. We determined the
health-related quality of life for patients living with hip fracture, correlated factors
and relationships with one-year health care resource utilization. METHODS: A
self-administered Medical Outcomes Study 36-item Short Form Survey (MOS SF-36)
questionnaire was mailed to patient after hospital discharge over 6 months. A
cross-sectional analysis of MOS SF-36 was carried out among 119 hip fracture pa-
tients of Chiangrai Hospital. Healthcare resource utilization was follow-up for one
year taken from hospital database. RESULTS: Response rate was 67 % and a mor-
tality rate after one year was 14%. The Cronbach’s alpha coefficients of eight items
symptoms domain, and of two items of summary score components for physical
function and mental function of MOS SF-36 Thai questionnaire were 0.769 and
0.831 respectively. The mean SD (95 % CI) for summary score components for
physical and mental functions were 40.111.6 (38.0-42.2) and 48.010.2 (46.1-49.9)
respectively. There was no significant difference of mean SD scores for global
health between gender (p0.103), age (65 and 65years) (p0.798), BMI (20.0
and 20.0kg/m2) (p0.693), hip fracture management types (surgical and nonsur-
gical) (p0.386) and types of hip fracture (p0.188) respectively. Presence of co-
morbidity was a highly correlated factor for summary score components for phys-
ical (p0.030), and mental (p0.001) functions. There was no significant correlation
between overall one year healthcare resource utilization with both summary score
components for physical (p0.567) and mental (p 0.357) functions.
CONCLUSIONS:Health-related quality of life assessments with MOS SF-36 for Thai
hip fracture patients are reliable. Thai hip fracture patients reflect poorer physical
functions than mental functions. Presence of co-morbid disease is a factor well
correlated with poorer health-related quality of life. There is no significant corre-
lation between one-year health care resource utilization and health-related quality
of life for Thai hip fracture patients.
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CONCEPTUAL MODEL OF THE IMPACT OF HIP FRACTURE ON PATIENTS’ LIVES
Kerr C1, Gallop K1, Nixon A1, Naegeli AN2, Zhao Y2, Burge RT2
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OBJECTIVES: Hip fractures are traumatic and debilitating events which are more
common in the elderly, and associated with loss of mobility and independence,
mortality, and significantly increased health care resources. Our objectives were to
evaluate the impact of hip fractures on patients’ lives and summarise the patient
experience in a conceptual model. METHODS: Twenty-one adults aged 50 years
who experienced a hip fracture in the previous 2-18 months were recruited to
participate in in-depth semi-structured interviews exploring their experience of
hip fracture and impacts on their life. Thematic qualitative analysis of interview
transcripts was conducted using ATLAS.ti software to identify areas of impact
(concepts) and explore the interrelationships between concepts. A conceptual
model was developed based on this analysis. RESULTS: Participants were mostly
female (n12) with mean age 75 years (range 53-87 yrs), and 5 participants had a
hip fracture treated with partial or total hip replacement. Pain and limited mobility
were commonly reported by participants and were associated with increased phys-
ical inactivity. Mobility limitations included: difficulties walking (distance, speed,
up/down stairs), restricted or difficult lower limb movements, getting or standing
up and driving. Restrictions to various activities (everyday, physical, leisure and
social) were reported as well as wide-ranging impact on patients’ sleep, energy
levels, independence, emotions, family and other relationships. Moderators of the
impact of hip fracture on patients were also identified and incorporated into the
conceptual model. CONCLUSIONS: The conceptual model summarizes important
experiences and related impacts of hip fracture from the patient’s perspective and
demonstrates the wide-ranging effects in other areas of patients’ lives during their
recovery.
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OBJECTIVES: To explore the impact of Dupuytren’s Disease (DD) on patients’ qual-
ity of life (QoL) and identify implications for clinical practice. A search of the liter-
ature failed to identify a patient-reported outcome measure for assessing the im-
pact of DD. The study was designed to be the first stage in the development of such
a measure. METHODS: The needs-based model of QoL was adopted and unstruc-
tured qualitative interviews were conducted with DD patients attending out-pa-
tients clinics. Data were transcribed and then underwent interpretative phenom-
enological analysis (IPA) to identify the key impact areas and common themes in
individuals’ personal experiences. RESULTS: Thirty-four DD patients (73.5% male;
aged 41-80; mean (SD): 64.2 (12.5) years) were interviewed. The sample had a wide
range of duration of DD (0.5-40; mean (SD) 12.6 (9.9) years). A total of 953 statements
relating to the impact of DD were identified from the interview transcripts. These
statements fell into 3 major categories of impact; emotional impairment (4 themes
including having no confidence in hand and being embarrassed), activity limita-
tions (10 themes including dressing, gripping and personal care) and QoL (11
themes including avoiding physical contact, self-consciousness and socialisation).
CONCLUSIONS: Dupuytren’s disease impacts on patients in three main areas;
emotional reactions, activity limitations and QoL. In any trial designed to deter-
mine the benefits of new interventions for the disease it is important to ensure that
each of these areas is assessed. It is intended to develop valid and reliable DD-
specific scales to cover each of these outcomes.
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RHEUMATOID ARTHRITIS TREATED WITH ADALIMUMAB IN GREECE:
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OBJECTIVES: Rheumatoid arthritis (RA) has been associated with significant de-
creases in a patient’s health-related quality of life (HRQL). Our objective was to
measure the HRQL of Greek RA patients treated with adalimumab. These outcomes
were assessed for differences between the results of a generic (EuroQol-5 Dimen-
sion [EQ-5D]) and an RA disease–specific (Health Assessment Questionnaire [HAQ])
instrument. METHODS: Data were drawn from an observational 52-week, single-
arm study that measured the effectiveness of adalimumab in the treatment of
patients with moderate to severe RA. Two instruments were implemented for re-
cording the HRQL during the study duration, the EQ-5D and the HAQ. All statistical
analysis was performed using SPSS software. RESULTS: The outcome measures
revealed that adalimumab is effective in treating patients with moderate to severe
RA. The mean utility score, as indicated by the EQ-5D questionnaire, increased
from 0.433 at baseline to 0.621 after 12 months of treatment. The mean disability
index, as indicated by the HAQ, decreased from 1.341 at baseline to 0.624 at the end
of treatment. Although both instruments reached the same conclusion, there was
only moderate correlation between the instruments (Spearman’s correlation at
baseline and at 12 months, r0.659 and r0.793, respectively). As expected, the
HAQ was more closely correlated with disease activity measures (swollen and
tender joints, visual analog scale [VAS] for pain assessment, and VAS for general
health assessment by both the patient and the physician) than the EQ-5D
questionnaire. CONCLUSIONS: Adalimumab is effective in the treatment of Greek
patients with moderate to severe RA. Caution should be taken in interpreting the
changes in HRQL when different outcome measures are used.
PMS69
EFFECTIVENESS THE TREATMENTS WITH NATURAL MINERAL WATER IN LOW
BACK PAIN FOR SPONDYLARTHROSIS
Ferreira MI1, Silva AJ2, Almeida A1
1Universidade da Beira Interior, Covilhã, Portugal, 2Comissão de avaliação técnica no âmbito do
termalismo da DGS, Covilhã, Portugal
OBJECTIVES:Determine whether treatments with Unhais da Serra natural mineral
water, a Portuguese spa, are effective in low back pain for spondylarthrosis.
METHODS: A descriptive, longitudinal, observational, uncontrolled prospective
study was conducted. The 51 study participants underwent 14 days of treatment
with Unhais da Serra natural mineral water. Assessment criteria were: pain inten-
sity (Visual Analogue Scale), quality of life (SF36v2), disability (ODIv2), absenteeism,
acute outbreak/relapse, drug consumption. The evaluation was conducted in four
distinct stages: the first day before, 14 days, 3 and 6 months after the thermal
treatment. RESULTS: The mean age of the sample was 60.53 years, 60.8% were
female. The duration of illness was, on average, 7.35 years, 50.9% were retired and
90.2% were from a countryside district. There was a statistically significant im-
provement (p 0.05) in pain intensity, quality of life, disability, absenteeism and
drug consumption, 14 days, 3 and 6 months after thermal treatment compared to
baseline. There was no effect on the number of acute outbreak/relapse. Regarding
socio-demographic and clinical data, we get no consistent results, only low corre-
lations and some differences in just a few moments of assessment.CONCLUSIONS:
This research showed that 14 days of treatment with natural mineral water of
Unhais da Serra spa, reduced pain, disability and drug consumption, improved
quality of life, not influencing the number of outbreaks acute/relapse presented by
the participants. All the beneficial effects were observed in the short and medium
term (six months). No consistent conclusion could be drawn to the possible influ-
ence of socio-demographic and clinical variables. Thus, treatment with Unhais da
Serra spa shows up as an effective complementary treatment modality in selected
patients with lumbar spondylarthrosis. It seems to be justified and useful to famil-
iarize patients and their physicians with this modality of treatment because the
socio-economic impact of the pathology.
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EVALUATION OF PRESCRIBED PAIN MEDICATIONS PRIOR TO THE INITIATION
OF DULOXETINE THERAPY IN A COMMERCIALLY INSURED POPULATION
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OBJECTIVES: Duloxetine is approved for the treatment of major depressive disor-
der (MDD) and general anxiety disorder (GAD), and for the management of diabetic
peripheral neuropathic pain (DPNP), fibromyalgia (FM), and chronic musculoskel-
etal pain, as studied in patients with osteoarthritis (OA) and chronic low back pain.
This study assessed pain medication use prior to duloxetine initiation among pa-
tients with each of these conditions. METHODS: US administrative claims were
used to identify commercially-insured duloxetine initiators 1/1/2009-3/31/2010
who had any of the 6 medical conditions mentioned above during the 12 months
prior to duloxetine initiation (defined as no duloxetine pill coverage in the previous
90 days). Utilization of pain medications including antidepressants, anticonvul-
sants, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and muscle relax-
ants was assessed over the 3, 6 and 12 months prior to duloxetine initiation.
RESULTS: The study identified 19,546, 5,764, 2,334, 15,362, 12,317, and 27,781 du-
loxetine initiators in the MDD, GAD, DPNP, FM, OA, and low back pain (LBP) groups.
Antidepressant use was high across all conditions over the 12 months prior to
initiation, especially among patients with MDD (84.4%) or GAD (79.9%). Anticonvul-
sant utilization was highest in DPNP (63.1%) and FM (51.9%), lowest in GAD (39.5%),
and similar among other groups (range: 42.8%-48.3%). Opioid use varied greatly
across groups (54.5-81.6%), with the lowest use among GAD patients and the high-
est use among LBP patients. GAD patients had the lowest NSAID use (32.9%), while
OA patients had the highest utilization (58.1%). The use of muscle relaxants ranged
between 29.4% (DPNP) and 56.7% (LBP) at 12 months prior to duloxetine initiation.
Pain medication use in the prior 3 and 6 months showed similar trends.
CONCLUSIONS: Patients used several types of pain medications prior to initiating
duloxetine across disease states. The trends in use were consistent 3, 6, and 12
months prior to duloxetine initiation.
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A POPULATION BASED ASSESSMENT OF OSTEOPOROSIS PREVALENCE AND
TREATMENT IN PRIMARY HEALTH CARE IN MADRID (SPAIN)
Sánchez-Piedra C, Parody Rúa E, González-Enríquez J, Imaz I, Sarría Santamera A
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OBJECTIVES: Osteoporosis represents a significant burden both to patients that
suffers from this condition, given the complications associated with this disease,
as well as to the health care system, given the elevated costs to treat this condi-
tions. Different options are considered in the treatment of osteoporosis, but there
are scanty assessments of this condition in large populations. The objective of this
study is to describe the population patterns of the prevalence of this disease as well
as main treatment trends in primary care centres (PCC) in Madrid. METHODS:
Information was gathered from electronic medical records of PCC of 7 areas of the
region of Madrid. Cross-sectional descriptive study from PCC database. This data-
base contains information about 1,318,020 patients who have visited PCC during
2006 and are older than 25 years-old. Patients with diagnosis of osteoporosis have
been identified. The use of pharmacological interventions (biphosphonate, ralox-
ifene, calcium) are described and compared considering sex, age, weight, height,
comorbidity, concomitant treatments, number of visits to the doctor and other
sociodemographic aspects. RESULTS: Overall, the prevalence of osteoporosis was
4.4%, being women 89.3% of reported cases. The median age was 64 years-old
(interquartile range 73-57). Osteoporotic patients used biphosphonates (33.1%),
raloxifene (3.29%), calcium (40,3%). A 14,3% of patients used only calcium. A 45.31%
of patients did not use calcium or other pharmacological treatments. The median
age of patients who used biphosphonates was 67, whereas the median age of
patients who did not use any treatment, including calcium, was 61. A 7.0% of
patients were referred to the traumatologist. CONCLUSIONS: Different treatment
strategies are considered among physicans of PCC in Spain to manage osteoporotic
patients. A relevant proportion of patients did not use any pharmacological inter-
vention. The treatment strategies used in osteoporosis seem to vary by age, and
should be adapted to individual risk factors.
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ASSESSMENT OF PRIOR USE OF PRESCRIBED PAIN MEDICATIONS AMONG
ELDERLY PATIENTS WHO INITIATED DULOXETINE
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OBJECTIVES: Duloxetine is approved to treat major depressive disorder (MDD) and
general anxiety disorder (GAD), and to manage the symptoms of diabetic periph-
eral neuropathic pain (DPNP), fibromyalgia (FM), and chronic musculoskeletal pain
as studied in patients with osteoarthritis (OA) and chronic low back pain. This
study assessed use of pain medications prior to duloxetine initiation among elderly
patients with each of these conditions. METHODS: Duloxetine initiators aged 65
with Medicare Supplemental Insurance in 2007, 2008 and during January 1, 2009-
March 31, 2010 who had any of the 6 medical conditions listed above during the 12
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